Lung Cancer News and Research

Latest Lung Cancer News and Research

Sicor Biotech receives FDA approval for tbo-filgrastim to treat severe neutropenia

The U.S. Food and Drug Administration today approved Sicor Biotech's tbo-filgrastim to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.

30 Aug 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

Allegro Diagnostics announces results from BronchoGen genomic test trial on lung cancer

Allegro Diagnostics today announced that results from its AEGIS (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trials, to determine the accuracy of the BronchoGen genomic test, have been accepted for an oral presentation during the late-breaking abstract session at CHEST 2012 on Tuesday, October 23, 2012 at 4:30 p.m. The abstract will also be published in a supplement of the October 2012 issue of CHEST.

28 Aug 2012

International Association for the Study of Lung Cancer receives ACCME accreditation

The International Association for the Study of Lung Cancer (IASLC) has been awarded Provisional Accreditation as a Continuing Medical Education (CME) provider by the Accreditation Council for Continuing Medical Education (ACCME).

26 Aug 2012

Statins reduce pancreatitis risk

Statins reduce the risk for pancreatitis in patients with normal or mildly elevated triglyceride levels, say the authors of a large meta-analysis.

24 Aug 2012

Vandetanib shows efficacy in thyroid cancer

The tyrosine kinase inhibitor vandetanib could significantly extend progression-free survival in patients with locally advanced or metastatic differentiated radioiodine-refractory thyroid cancer, show results of a small phase II randomized trial.

24 Aug 2012

Radiating fears over diabetes in childhood cancer survivors

People who undergo pancreatic irradiation during childhood cancer therapy are at an increased risk for developing diabetes later in life, report researchers.

24 Aug 2012

GlcNAc plays a key role in keeping cancerous monsters ‘fed’

Behaving something like ravenous monsters, tumors need plentiful supplies of cellular building blocks such as amino acids and nucleotides in order to keep growing at a rapid pace and survive under harsh conditions. How such tumors meet these burgeoning demands has not been fully understood.

24 Aug 2012

Results from Biodesix VeriStrat phase II advanced lung cancer trials

Biodesix today announced that VeriStrat results from two phase II advanced lung cancer trials will be presented at the upcoming 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

24 Aug 2012

Common diabetes treatment may cause bladder cancer

A commonly used diabetes treatment may increase patients’ risk for bladder cancer, show US study findings.

22 Aug 2012

Spicy solution for viral infection

Curcumin, the main compound in the spice turmeric, prevents replication of mosquito-borne Rift Valley Fever virus in infected cells, report researchers.

22 Aug 2012

Gene therapy applied to peripheral arterial disease

Hepatocyte growth factor gene therapy could be used to treat patients with severe peripheral arterial disease, suggest results of a phase I clinical trial.

21 Aug 2012

New tool reveals surprising clues about how cancer cells respond to therapy

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments.

21 Aug 2012

New model more effective in predicting individuals at high risk of lung cancer

A lung cancer risk prediction model developed by scientists at the University of Liverpool has been shown to be a viable tool for selecting high risk individuals for prevention and control programmes.

21 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012